Shares of top-German, pharmaceutical and chemical giant, Bayer AG (BAYN.DE) fell today the most since March, as Washington state court will review a case alleging potentially toxic chemicals from the Monsanto, Bayer unit (completed acquisition in 2018). In such case, three teachers claim that, Monsanto product caused brain injuries.
The court denied an application for a 'speedy' review of this case. According to Bloomberg Intelligence report, Bayer’s exposure to the Roundup litigation (another Monsanto's product) could exceed the Bayer's almosta $16 billion reserve by around 5%. German company has more than 57k unfinished cases related to Roundup; still claiming that Roundup is totally safe.
Bayer AG (BAYN.DE, D1 interval)
As we can see below, Bayer shares failed to break above resistance of the EMA200 (red line) and now are falling back to levels unseen since half-September.
Source: xStation5
Oracle shares fall 6% amid fears of financial troubles 🔎
Lennar dips 4.6% after publishing quarterly earnings💡
DE40: Many informations, few movements
From Euphoria to Correction: CoreWeave and the Future of AI Infrastructure
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
